A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
← catalyst calendarNCT07043946 · readout ≤ 377 d
Sponsored by Climb Bio, Inc. (industry) · CLYM — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24estimated
Sites
20
Countries
Bulgaria, Greece, Serbia +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Immune Thrombocytopenia (ITP)
- ITP
- Biologics
- Monoclonal
- Anti-CD19
Intervention
- Drug: Budoprutug — also filed as TNT119
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to week 48
Permalink · CLYM's whole pipeline · Catalyst calendar · Every registered study · What changed